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Background
Multifocal motor neuropathy (MMN) is consid-
ered an acquired immune-mediated neuropathy 
characterized by exclusive involvement of periph-
eral motor nerves, asymmetric distribution and 
conduction block detected on neurophysiological 
examination. The clinical course is slowly progres-
sive and can lead to severe disability. The diagno-
sis is made on the basis of clinical, electrodiagnostic 
and laboratory features, but is sometimes difficult 
in patients with atypical or overlapping presenta-
tions. Various sets of diagnostic criteria have been 
proposed for MMN [Van Den Berg-Vos et  al. 
2000; Olney et al. 2003; European Federation of 
Neurological Societies, 2010].
Several placebo-controlled trials have demon-
strated the efficacy of high-dose intravenous 
immunoglobulin (IVIG) therapy for MMN 
[Azulay et  al. 1994; Van Den Berg et  al. 1995; 
Federico et al. 2000; Léger et al. 2001]. Although 
cyclophosphamide has also been described as 
effective in uncontrolled studies, IVIG is the pre-
ferred first-line treatment due to its solid safety 
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Abstract
Objectives: The management of patients with multifocal motor neuropathy (MMN) under 
everyday clinical conditions has been insufficiently studied. We therefore collected 
comprehensive observational data on patients with MMN who received intravenous (IV) or 
subcutaneous (SC) immunoglobulins (IGs) as maintenance therapy.
Methods: This was a prospective, noninterventional study (registry) in neurological centres 
(hospitals and offices) throughout Germany.
Results: As of 1 December 2015, 80 patients with MMN were included (mean age 55.4 ±  
9.8 years, 67% males, mean disease duration 10.7 ± 10.2 years). The affected limb regions 
were predominantly distal muscle groups of the upper extremities. On the inflammatory 
neuropathy cause and treatment (INCAT) scale, 94% of the patients had some disability in 
the arms and 61% in the legs. At inclusion, 98.8% received IVIG and 1.3% SCIG. Substantial 
variation was observed between IVIG treatment intervals (every 0.7 to 17.3 weeks) and dosage 
(0.2–2.1 g/kg body weight received during a single administration; mean monthly dosage,  
0.9 g/kg body weight). However, the mean monthly dosage was steady over time. At 1-year 
follow up, improvement was seen in muscle strength, INCAT and quality of life (QoL) scores 
(SF-36 questionnaire).
Conclusions: The management of patients with MMN in everyday clinical practice 
demonstrates a wide range of absolute dosages and treatment intervals of IG, supporting 
the recommended practice of determining treatment dose on an individual patient basis. The 
improvements in muscle strength and reduction in disability, accompanied by increased QoL, 
strengthen the case for use of IG as a maintenance treatment for MMN.
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profile. A meta-analysis by the Cochrane collabo-
ration of four randomized controlled trials on 
IVIG for MMN, that included 34 patients in 
total, indicated a beneficial effect on muscle 
strength [Van Schaik et  al. 2005]. These con-
trolled trials of IVIG were the basis for regulatory 
approval of some IVIG preparations for the treat-
ment of MMN [Elovaara et  al. 2008; Stangel, 
2010]. Although not approved, there are also sev-
eral reports of successful treatment of MMN with 
subcutaneous immunoglobulins (SCIGs) [Eftimov 
et al. 2009; Harbo et al. 2009, 2010; Misbah et al. 
2011]. The exact immunomodulatory mecha-
nisms of action of IVIG (or SCIG) are not yet 
known, but it is thought that several immune sys-
tem players are targeted, including B cells, T cells, 
macrophages, complement, cytokines or cellular 
adhesion molecules [Schwab and Nimmerjahn, 
2013; Dalakas, 2014].
Although the short-term benefit of IVIG treat-
ment for MMN is unequivocal and can even be 
used as a diagnostic criterion in atypical cases, the 
data on long-term IVIG treatment are limited. 
Often, muscle strength declines despite treat-
ment, and an increase in IVIG dose is necessary 
[Terenghi et al. 2004]. Furthermore, due to the 
low incidence of the disease, observational data 
on the presentation and management of patients 
with MMN in clinical practice are usually limited 
to small cohorts and retrospective analyses [Cats 
et al. 2010; Cocito et al. 2014]. Thus, we aimed to 
systematically collect prospective data in the con-
text of a large longitudinal observational study 
under everyday clinical conditions. The SIGNS 
study focuses on the utilization of immunoglobu-
lin (IG) preparations and clinical outcomes across 
a broad spectrum of centres and indications, 
respectively, and includes a specific module on 
patients with MMN. The aim was to describe the 
clinical properties of a large German cohort of 
MMN patients, their management and treatment 
in everyday clinical practice and their quality of 
life (QoL). In addition, we sought to compare 
these with published data from other cohorts.
Methods
Study design
SIGNS (assessment of IG treatment in a long-
term noninterventional study) is an ongoing pro-
spective, observational study (registry type), with 
consecutive inclusion of eligible patients [Kirch 
et al. 2012]. The study is performed in agreement 
with the Declaration of Helsinki in its latest revi-
sion, and according to the principles of good epi-
demiological practice. The study was approved 
by the ethics committee of the Medical Faculty of 
the Technical University of Dresden, and further 
local ethics committees in Germany. Patients 
were only included if they provided written 
informed consent. All patient data are processed 
in a pseudonymized format; that is, only the treat-
ing physician knows the identity of his or her indi-
vidual patient. The ClinicalTrials.gov identifier is 
NCT01287689.
Currently, 88 centres throughout Germany are 
taking part in the study. These include university 
hospitals, community hospitals and office-based 
physicians.
Patients and parameters
Documentation of patients with MMN started in 
September 2010. Patients of either gender and of 
any age group were eligible for documentation if 
they received any IG preparation as long-term 
therapy or as newly initiated therapy for neuro-
logical autoimmune disease. In addition, primary 
and secondary immunodeficiencies were docu-
mented in the registry [Kirch et al. 2010, 2012]. 
Visits were scheduled every 6 months, and the 
intended observation period was at least 2 years 
per patient.
Information was collected on application route 
[subcutaneous (SC) or intravenous (IV)] and 
dosage of IGs, frequency of IG administrations 
and days of treatment with IG. Information on 
MMN was collected using the protocol of Cats 
and colleagues as a template [Cats et al. 2010], 
with additional information on previous (tenta-
tive) diagnoses, electrophysiology and nerve con-
duction. The diagnostic criteria applied as per 
protocol were those proposed by the European 
Federation of Neurological Societies/Peripheral 
Nerve Society (EFNS/PNS) issued in 2006 
[European Federation of Neurological Societies/
Peripheral Nerve Society, 2006].
Data were collected on disease duration, time to 
diagnosis, clinical symptoms, neurological func-
tion, physical function using the inflammatory 
neuropathy cause and treatment (INCAT) disabil-
ity scale, QoL and stabilization or progression of 
symptoms over time. Muscle strength was assessed 
according to Medical Research Council (MRC) 
criteria [Kleyweg et  al. 1991]. The following 
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muscles were assessed on both sides: upper arm 
abductors, elbow flexors, wrist extensors, hip flex-
ors, knee extensors and foot dorsal flexors. In our 
study, scores were collected as 0–3 (combined 
integers), 4 and 5. Thus, an MRC sum score as 
published in some recent publications [Eftimov 
et  al. 2009; Markvardsen et  al. 2013] was not 
computed.
As an activity and participation measure, the 
INCAT disability score [Hughes et al. 2001] was 
applied to capture daily activities such as doing 
and undoing buttons and zips, washing and 
brushing hair, using knife and fork together and 
handling coins. The leg scale measures problems 
with walking, taking into account the use of aids. 
The INCAT scales range from 0 (no signs of dis-
ability) to 5 (most severe disability score), with 
separate subscores generated for arm and leg dis-
ability. The overall INCAT score is the sum of 
the two scores.
For the assessment of QoL, the Short Form 
36-item (SF-36) [Ware and Sherbourne, 1992], 
EQ-5D [Fahrenberg et al. 2000], life satisfaction 
(LFZ) [Greiner et  al. 2005] and WHO-5 ques-
tionnaires (see http://www.cure4you.dk/354/
index.php?a=e2&ei=4151) were administered. 
These questionnaires have been validated in a 
German version and are generic, that is, can be 
used across various indications or diseases. 
Questionnaires were (and are planned to be in the 
future) completed at least once a year to allow for 
longitudinal analyses. Diaries, in which patients 
were asked to document their exercise activities, 
nonpharmacological treatments and any medical 
treatments undertaken, were handed out to the 
patients every 6 months.
Data entry and statistical analysis
Data were entered in an online electronic data 
capture system. During data entry, automatic 
plausibility checks were performed for complete-
ness and accuracy. Data were checked by statisti-
cal methods centrally on a quarterly basis and, if 
required, queries were sent to the centres. 
Monitoring visits for source data verification were 
performed in randomly selected centres. Cut off 
for the present analysis was 1 December 2015.
Descriptive statistics (mean and standard devia-
tion, or median and range) were used for continu-
ous variables. Categorical variables were described 
as counts and percentages of subjects. Statistical 
analyses were performed using IBM SPSS 
Statistics Version 19.0.
Results
In the SIGNS registry, 23 centres included 81 
patients with MMN (range, 1–18 per centre), 
between September 2010 and December 2015. 
Of those, one patient with Lewis–Sumner syn-
drome (or MADSAM) was excluded. The mean 
observation duration of the analysed 80 MMN 
patients was 20.9 ± 11.5 months.
Diagnostic criteria for MMN
The MMN diagnosis of physicians was not adju-
dicated by a third party, as it was the purpose of 
the study to document diagnostic procedures and 
patient management under real-life conditions. 
Nerve conduction was reported in only 91% of 
the included patients, and not all fulfilled the 
EFNS/PNS criteria for conduction block, how-
ever, some fulfilled the criteria partially and the 
patients without conduction block had a positive 
clinical response to IgG and thus were regarded 
as MMN patients in line with the findings of 
Delmont and colleagues [Delmont et al. 2006].
Patient characteristics
The characteristics of patients with MMN at inclu-
sion are displayed in Table 1. More male (54) than 
female (26) patients were documented. The mean 
age of the MNN patients at inclusion into the study 
was 55.4 ± 9.8 years. Mean disease duration was 
10.7 ± 10.2 years. There was a substantial time lag, 
ranging from 0 to 57 years, with a mean of 4.4 years, 
between the occurrence of first symptoms and the 
diagnosis of the disease. The initial (suspected) 
diagnosis was MMN in 42 cases (57.5%), motor 
neuron disease or amyotrophic lateral sclerosis 
(ALS) in eight patients (11.0%), ‘motor neuropa-
thy’ in five patients (6.8%), chronic inflammatory 
demyelinating polyradiculoneuropathy (CIDP) in 
four patients (5.5%), radiculopathy in three patients 
(4.1%) and other diseases in the remaining patients 
(15.1%), including Lewis–Sumner Syndrome 
(MADSAM), neuroborreliosis, sensorimotor neu-
ropathy, sulcus ulnaris syndrome, hereditary 
neuropathy and polyneuropathy (Table 2).
The first symptom was most often: reduced grip 
strength of the hand (35.6%), weak dorsiflexion 
of the foot (23.3%) or weakness of the finger 
extensors (11.0%) (Table 3).
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The majority of patients had up to three affected 
limb regions at inclusion (Table 4). Muscle weak-
ness was reported in 80.0%, muscle atrophy in 
60.0%, limited endurance in 52.5%, muscle 
twitching 38.8% and muscle cramps in 33.8% of 
patients.
Table 1. Characteristics of multifocal motor neuropathy (MMN) patients at inclusion.
Characteristic SIGNS (n = 80) Dutch cohort (n = 88)*
Age (years) at inclusion 55 (range 29–76) 52 (range 27–78)
Sex ratio, male: female 54 (67.5%): 26 (32.5%) 64 (73%): 24 (27%)
Body mass index, kg/m2 26.1 ± 3.8 nr
Symptom/disease duration at inclusion (years) 8.6 (range 0.1–60) 11 (range 2–43)
Age (years) at symptom onset 45 (range 17–69) 40 (range 22–66)
Disease duration since diagnosis (years) 6.3 (range 0–27) nr
Values are mean ± standard deviation or percentages, if not specified otherwise.
nr, not reported.
*Source: Cats et al. [2010].
Table 2. Initial diagnosis.
SIGNS (n = 73/80) Dutch cohort (n = 88)*
Initial diagnosis n (%) n (%)
MMN 42 (57.5) 31 (35)
Motor neuron disease 8 (11.0) 28 (32)
Mononeuropathy 5 (6.8) 11 (13)
Polyneuropathy 3 (4.1) 13 (15)
Radiculopathy 3 (4.1) 2 (2)
CIDP 4 (5.5) 1 (1)
Hereditary neuropathy 1 (1.4) 1 (1)
Minor stroke  0 1 (1)
Other** 7 (9.6)  0
*Source: Cats et al. [2010].
** Including ganglionitis (shoulder), Guillain–Barré syndrome, Lewis–Sumner syndrome (MADSAM), neuroborreliosis, 
sensorimotor neuropathy, sulcus ulnaris syndrome (n = 2).
MMN, multifocal motor neuropathy; CIDP, chronic inflammatory demyelinating polyradiculoneuropathy.
Table 3. First symptoms.
Symptoms SIGNS (n = 73/80) Dutch cohort (n = 88)*
n (%) n (%)
Reduced grip strength hand 26 (35.6) 22 (25)
Reduced dexterity hand 6 (8.2) 18 (21)
Extension weakness of fingers 8 (11.0) 14 (16)
Weakness adduction upper arm 2 (2.7) 4 (5)
Femoral weakness 3 (4.1)  0
Weak dorsiflexion of foot (foot drop) 17 (23.3) 28 (32)
Reduced mobility toes 2 (2.7) 2 (2)
Other 8 (11.0)  0
Unknown 1 (1.4)  0
*Source: Cats et al. [2010].
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As sensory symptoms are absent in MMN, most 
patients had no sensory abnormalities (78.8%). 
Only few had formication (2.5%), an electrifying 
sensation (3.8%), pins and needles (2.5%), and 
some, a numbness (15.0%).
Nerve conduction was documented in 73 of the 
80 included patients. Conduction block was 
reported in 54 patients (74%). In 41 of these 
(75.9%) (Table 5), the conduction block was 
assessed according to EFNS/PNS criteria.
The majority of MMN patients were categorized 
as stable with deficits at the beginning of the study 
(n = 58, 79.4%). Fewer patients were progressive 
or relapsed (n = 7, 9.6%) or stable with no defi-
cits while undergoing treatment (n = 5, 6.8%).
Muscle strength and disability
In the detailed analysis of muscle strength accord-
ing to MRC criteria (Figure 1), available for 63 
patients, normal strength was observed in one 
patient, reduced strength in the arms in 47 
patients (78.3%), in the hands in 57 patients 
(90.5%) and in the legs in 34 patients (56.7%).
On the INCAT disability scale, 5.6% of the 
patients had no limitations in the arms and 38.9% 
had none in the legs (Figure 2). A substantial pro-
portion of patients (24.3%) had improved at 1 
year in the INCAT score compared with baseline, 
while 54.1% remained unchanged. In the 
improved patients, the INCAT score was mostly 
reduced by 1 point (16.2%), or by 2, 3, or even 5 
points, respectively (2.7% each, Table 6).
Treatment at inclusion and after 1 year
The great majority of patients (63, or 79%) had 
already been on IG maintenance therapy for at 
least 3 months; only 16 (20%) were on newly initi-
ated therapy. At inclusion, all 80 patients were 
treated with 6 different IV preparations (in 64%, 
Table 4. Number of affected limbs at inclusion.
Affected limb regions* SIGNS (n = 63/80) Dutch cohort (n = 88)**
Number n (%) n (%)
0 (only hands) 8 (12.7) –
1 11 (17.5) 12 (14)
2 17 (27.0) 15 (17)
3 9 (14.3) 13 (15)
4 2 (3.2) 19 (22)
5 3 (4.8) 12 (14)
6 4 (6.3) 11 (13)
7 3 (4.8) 2 (2)
8 6 (9.5) 4 (5)
*Maximum eight regions: upper arm and lower arm on both sides; upper leg and lower leg on both sides.
**Source: Cats et al. [2010].
Table 5. Results of nerve conduction tests at inclusion.
n %
MMN diagnosis MMN with conduction block 54 74.0
MMN without conduction block 19 26.0
Total 73 100.0
MMN with conduction block (n = 54) 
diagnosed according to EFNS/PNS 
criteria
No 9 16.7
Yes 41 75.9
nr 4 7.4
Data on nerve conduction studies were reported in 73 of the 80 included patients.
MMN, multifocal motor neuropathy; nr, not reported; EFNS, European Federation of Neurological Societies; PNS,  
Peripheral Nerve Society.
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Kiovig, which was approved for this indication in 
Germany in 2011) and 1 SC preparation (Table 7).
On average, MMN patients received IVIG at a 
mean monthly (4-week) dose of 0.9 g/kg body 
weight (BW) (median 0.7 g/kg BW: minimum 0.1 
g/kg BW, maximum 2.9 g/kg BW). The mean IG 
application interval was 4.8 weeks (median 4.0 
weeks: minimum 0.7 weeks, maximum 17.3 
weeks). The absolute dosage per infusion cycle 
was 0.8 ± 0.5 g/kg BW, range 0.2– 2.1, median 
0.7 and interquartile range 0.4–1.0. Thus, dosage 
varied substantially among patients (Figures 3a 
and 4b). While in 63.9% of MMN patients there 
was no dose change between baseline and 1 year, 
in selected patients there were substantial changes 
(−70% to ⩾100%). Nevertheless, compared with 
baseline, at 1 year the median dose had hardly 
changed, though the variance in dosing decreased. 
Average doses (and dosing intervals) were stable 
during the follow-up period (Figure 4).
Only five patients received further immunosuppres-
sive or immunomodulatory treatment in addition to 
IgG (one patient had cyclophosphamide until 6 
months, one patient had cyclophosphamide until 
year 1, one patient had steroids until 18 months, 
one patient started tocilizumab at 1 year and one 
patient started cyclophosphamide at 1.5 years). All 
other patients did not receive further add-on ther-
apy even in the case of clinical deterioration.
Nonpharmacological therapy
According to patient diaries, a majority of patients 
who filled out the questionnaires did physical 
exercise or sports on a regular basis. For example, 
in the first 6 months after inclusion, 39 of 46 
(85%) of the MMN patients, and in months 
7–12, 26 of 32 (81%) patients reported regular 
exercise. Prescribed nonpharmacological inter-
ventions addressing the neurological disease 
mostly consisted of physiotherapy (52%).
Figure 1. Muscle strength according to Medical Research Council (MRC) criteria.
BL, baseline.
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Figure 2. Degree of disability on the INCAT scale in MMN patients documented in SIGNS.
INCAT, inflammatory neuropathy cause and treatment.
Arm disability
0 No upper limb problems
1 Symptoms, in one or both arms, not affecting the ability to perform any of the following functions: doing all zips and 
buttons; washing or brushing hair; using a knife and fork together; handling small coins
2 Symptoms, in one arm or both arms, affecting but not preventing any of the abovementioned functions
3 Symptoms, in one arm or both arms, preventing one or two of the abovementioned functions
4 Symptoms, in one arm or both arms, preventing three or all of the functions listed, but some purposeful movements still 
possible
5 Inability to use either arm for any purposeful movement
Leg disability
0 Walking not affected
1 Walking affected, but walks independently outdoors
2 Usually uses unilateral support (stick, single crutch, one arm) to walk outdoors
3 Usually uses bilateral support (sticks, crutches, frame, two arms) to walk outdoors
4 Usually uses wheelchair to travel outdoors, but able to stand and walk a few steps with help
5 Restricted to wheelchair, unable to stand and walk a few steps with help
Source: Merkies et al. [2002].
Table 6. Changes on the INCAT disability scale at 1 year compared with inclusion: (a) in categories; (b) in points.
(a)
n %
Arm Worsening 7 18.9
 Unchanged 25 67.6
 Improvement 5 13.5
 Total 37 100.0
Leg Worsening 24 64.9
Unchanged 8 21.6
Improvement 5 13.5
Total 37 100.0
INCAT total Worsening 8 21.6
Unchanged 20 54.1
Improvement 9 24.3
Total 37 100.0
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Quality of life
On the EQ-5D, the mean index was 0.8 ± 0.2. 
The overall state of health on the 100-point visual 
analogue scale was 38.4 ± 19.7. Further, QoL 
was assessed with the SF-36 in eight main 
domains as shown in Figure 5. Compared with an 
unselected sample of the German general popula-
tion, QoL of patients with MMN was reduced in 
all domains, in particular ‘social functional capa-
bility’, ‘physical functional capability’ and ‘physi-
cal role function’. On average, QoL as measured 
by SF-36 was 38.6 ± 10.9 on the physical scale 
Table 6. (Continued)
(b)
n %
Arm Worsening +1 6 85.7
 +2 1 14.3
Unchanged 0 25 100.0
Improvement –3 1 20.0
 –2 2 40.0
 –1 2 40.0
Total –3 1 2.7
 –2 2 5.4
 –1 2 5.4
 0 25 67.6
 +1 6 16.2
 +2 1 2.7
Leg Worsening +1 11 45.8
+2 9 37.5
+3 4 16.7
Unchanged 0 8 100.0
Improvement –2 2 40.0
 –1 3 60.0
Total –2 2 5.4
–1 3 8.1
0 8 21.6
+1 11 29.7
+2 9 24.3
+3 4 10.8
Change INCAT 
total score
Worsening +1 6 75.0
+3 1 11.1
+4 1 11.1
Unchanged 0 20 100.0
Improvement –5 1 11.1
–3 1 11.1
–2 1 11.1
–1 6 66.7
Total –5 1 2.7
–3 1 2.7
–2 1 2.7
–1 6 16.2
0 20 54.1
+1 6 16.2
+3 1 2.7
+4 1 2.7
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Table 7. Immunoglobulins at inclusion and at 1-year follow up.
Treatment characteristic Baseline (n = 80*) 1-year follow up (n = 59)
 n (%) n (%)
Newly initiated treatment (treatment duration 
< 3 months after entry)
16 (20.3%) –
Maintenance treatment 63 (79.7%) –
Mean treatment duration at inclusion (months 
± SD)
23.3 ± 29.8 –
IVIG preparation  
Kiovig 51 (63.7%) 37 (62.7%)
Gamunex 10% 10 (12.5%) 7 (11.9%)
Intratect 3 (3.8%) 3 (5.1%)
Octagam 5% 2 (2.5%) 1 (1.7%)
Octagam 10% 1 (1.3%)  0
Privigen 12 (15.0%) 7 (11.9%)
SCIG preparation  
Hizentra 20% 1 (1.3%) 1 (1.7%)
Subcuvia 16%  0 1 (1.7%)
Treatment interruption – 2 (3.4%)
IG prescribed at:  
Hospital based 17 (21.3%) 6 (10.2%)
Outpatient clinic 35 (43.8%) 24 (40.7%)
Office based 26 (32.5%) 25 (42.4%)
Other institution 2 (2.5%) 4 (6.8%)
*For one patient, previous treatment was unknown.
IG, any immunoglobulin (intravenous or subcutaneous); IVIG, intravenous immunoglobulin; SCIG, subcutaneous  
immunoglobulin.
Figure 3. IV Dosing of intravenous immunoglobulin (IVIG) preparations in patients with MMN at baseline and 
at follow up.
(a) Per patient.
IVIG, intravenous immunoglobulin; BW, body weight.
Each line represents an individual patient.
(b) In dosage categories.
IVIG dosage at inclusion:
0.9 ± 0.7 g/kg BW/4 weeks, range 0.1–2.9, median 0.6 [interquartile range (IQR), 0.3–1.3].
IVIG dosage at 1 year:
MMN: 0.9 ± 0.7 g/kg BW/4 weeks, range 0.1–3.0, median 0.6 (IQR, 0.4–1.3).
MMN, multifocal motor neuropathy; IQR, interquartile range.
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and 44.4 ± 10.6 on the mental scale; at 1 year, 
the values were 39.1 and 47.1, respectively.
The current state of health, according to ques-
tion 12 on the SF-36, was categorized by the 
majority of patients as good or moderate (27% 
and 48%, respectively, Figure 6a). At 1 year, in 
response to the question ‘Compared with one 
year ago, how would you rate your health in 
general now?’, 50% of the patients considered 
Figure 4. Dosing changes at 1-year follow up compared with at inclusion.
Values are %.
Figure 5. Quality of life in Short Form-36 at the time of inclusion.
Higher values indicate better status, range [0–100].
Norm control from German representative sample for normative comparison.
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themselves as stable, while 30% of patients stated 
improvement and 20% reported deterioration 
(Figure 6b).
Discussion
This analysis of the SIGNS study provides cur-
rent insights regarding the characteristics and 
management of patients with MMN on IG as 
maintenance therapy, as documented by experi-
enced neurologists throughout Germany.
Demographic data and disease characteristics
We collected a set of data similar to that of a 
nationwide Dutch cross-sectional study on 88 
patients with MMN performed in 2007 [Cats et al. 
2010]. In both studies, there were more men than 
Figure 6. Global health as measured with the Short Form-36.
(a) At baseline: ‘In general, would you say your health is?’.
For comparison, values derived from the German population for this question are displayed [Morfeld et al. 2005]. For the 
German version of the SF-36, translation of this question deviates from the original English version; shown here are back-
translated German answer categories.
(b) At follow up: ‘Compared with one year ago, how would you rate your health in general now?’.
Values are %.
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women; however, our study did not include all 
patients in Germany and thus the data do not 
match an exact epidemiological or demographic 
group. Nevertheless, the similarity in gender distri-
bution, mean age and similar disease duration sug-
gests that we investigated a representative patient 
population. The differential diagnosis of MMN 
appears to pose problems for primary care physi-
cians, as both in SIGNS and in the abovemen-
tioned Dutch study, a considerable portion of 
patients initially were given other diagnoses (42% 
and 35%, respectively). In both studies, reduced 
grip strength of the hand (SIGNS, 35.6%; Dutch, 
25%) and weak dorsiflexion of the foot (SIGNS, 
23.3%; Dutch cohort, 32%) were noted as the two 
most frequent symptoms at onset. Thus, clinical 
presentation was relatively homogenous, with the 
onset of disease often asymmetric, predominantly 
in distal muscle groups and with upper extremities 
more often affected than lower extremities in terms 
of weakness [Dimberg, 2009, Cats et al. 2010].
Treatment
IG is recommended as a first-line therapy for 
MMN to improve muscle strength [Van Schaik 
et al. 2006]. In Germany, more than 15 different 
IG preparations for IV and SC use are available; 
however, only one IVIG preparation (Kiovig) has 
been approved for MMN. The data in SIGNS 
indicate that a substantial portion of patients are 
treated ‘off label’, that is, with IG preparations 
that have not received approval as treatments for 
MMN. On the one hand, this is due to the fact 
that at the beginning of recruitment for the study, 
no IG preparation had specifically been licensed 
for MMN, and patients continued on the prepa-
ration that they were being treated with before 
approval. On the other hand, it seems that prepa-
rations might be considered interchangeable by 
physicians with regard to treatment efficacy.
It is recommended that dosing and administration 
intervals of IG be individually titrated [EFNS, 
2010]. In a recent randomized study by Hahn and 
colleagues, the mean monthly IG dose was 1.2 ± 0.5 
g/kg BW [Hahn et al. 2013]. In SIGNS, dosing pat-
terns vary substantially (between 0.1 and > 0.9 g/kg 
BW per 4 weeks), reflecting individualized treatment 
regimens. It is notable that dosing remained con-
stant or was only slightly changed in the majority of 
patients over the course of 1 year. Notably, authors 
of a retrospective study found reliably good short-
term response to IVIG, but declining effectiveness in 
long-term follow up of patients [Léger et al. 2008], 
that was confirmed by other studies [Van Den Berg-
Vos et  al. 2002; Terenghi et  al. 2004], while in 
another study their IgG effectiveness persisted 
[Vucic et al. 2004]. In our study, IgG treatment was 
stopped in only one patient who did not have a clini-
cal benefit from the treatment. All other patients 
required further infusions that were decided on clini-
cal grounds since they got worse when the infusions 
were delayed. However, the average follow up of 1.5 
years may be too short to finally assess the long-term 
response to IVIG.
Overall, the SIGNS data from everyday practice 
show that IGs are administered as recommended 
by international guidelines on an individual basis 
[EFNS, 2010].
Muscle strength and disability
Severe limitation in muscle strength (score 0–3 
on the MRC scale) was the exception in our 
patient population. IG treatment improved mus-
cle strength (MRC) and reduced disability 
(INCAT) in most patients after 1 year. Weakness 
is the only determinant of disability in MMN, 
and improving strength will improve disability 
[Van Schaik et  al. 2006]. The INCAT score, 
which we used similarly to other trials in patients 
with immune neuropathies [Hughes et al. 2008], 
has some shortcomings. These include the failure 
to properly capture limitations due to proximal 
arm weakness or fatigue (which lowers content 
validity), or heavy-item weighting due to the 
inclusion of only two functions [Breiner et  al. 
2014]. Among the strengths of the INCAT are 
the ease of administration, attention to both 
upper and lower limb dysfunction, good reliabil-
ity and high responsiveness to change [Breiner 
et  al. 2014]. Our data demonstrate that most 
patients with MMN are stable or improve after 
long-term treatment with IG.
QoL
On the SF-36, one of the most widely used generic 
instruments, patients presented with values of 40 
to 67 in the 8 different domains, which represents 
substantially impaired QoL and functionality in 
comparison with normal samples derived from a 
German population [Morfeld et al. 2005] (see also 
http://www.sf-36.org/research/sf98norms.pdf). 
Nevertheless, almost one third of the patients rated 
their overall health as ‘good’. It should be noted 
that satisfaction with health does not mean absence 
of disease; that may explain why many patients 
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with neurological autoimmune diseases  do not 
differ much from individuals in the general popula-
tion in this respect [Bellach, 2000]. Thus, although 
many patients with MMN have an impaired QoL, 
most are nevertheless satisfied with their treatment 
and their overall condition, in spite of persistent 
neurological disability. This underscores the fact 
that even though the treatment may not lead to a 
full recovery, maintenance IG therapy is important 
for the sake of upholding QoL.
Methodological considerations
The current SIGNS registry is prospective and 
recruits consecutive patients, aiming to reduce 
selection bias. It applies various measures for 
quality assurance, the most important being sys-
tematic plausibility checks, queries based on sta-
tistical checks (e.g. on outlier values), as well as 
on-site monitoring with systematic comparisons 
between study data and patient files.
The main limitations of this study are those inher-
ent in any registry. Given that this is an observa-
tional, nonrandomized study, different biases can 
obscure true causal association [Delgado-
Rodriguez and Llorca, 2004]. Clinical decisions 
by the treating physicians may assign patients to 
different IG preparations (or other drugs) based 
on disease severity, disease duration, presence of 
comorbidities and other factors. This can poten-
tially introduce allocation or channelling bias and 
confound the association between treatment and 
outcomes. In our registry, there is no re-evalua-
tion of patients, which may result in some inclu-
sion of patients with unconfirmed diagnoses. 
Also, in the Dutch study of Cats and colleagues, 
the application of different diagnostic criteria 
would have led to the noneligibility of approxi-
mately 15% of patients [Cats et al. 2010].
Data on neurophysiology were incomplete in our 
study and the follow-up examinations were neither 
mandatory nor standardized as a follow-up exami-
nation. Thus, data on conduction block in the fol-
low-up examinations are few and were not included 
in the analysis due to too many data lacking.
However, as mainly specialist centres are involved, 
the quality of diagnosis should be high, and indeed 
is based on established criteria in the great majority 
of cases. Still, the inclusion of expert centres might 
not reflect the true picture of MMN management 
in Germany (especially in small centres). Also, 
extrapolation of the results to other, especially 
non-European, countries may only be made with 
caution. Information on side effects (other than 
serious adverse drug reactions) was not collected, 
so no statement can be made about the tolerability 
of IG preparations in the described setting.
Even taking all these limitations in account, our 
study confirms the presentation and diagnostic 
difficulties observed in other patient populations 
[Cats et  al. 2010]. This delays treatment and 
probably also leads to a higher proportion of 
patients with permanent axonal damage and neu-
rologic disability. Thus, early diagnosis and treat-
ment of MMN is warranted, as our data show that 
maintenance therapy can halt or even improve 
both muscle strength and QoL.
Conclusion
In conclusion, the results of this analysis confirm 
the previously reported phenotype of MMN 
under clinical practice conditions. Most patients 
with MMN are treated with an individualized 
regimen in dosing and interval as recommended 
by international guidelines. The improvements in 
muscle strength and reduction in disability, 
accompanied by increased QoL, further 
strengthen the case for use of IG as maintenance 
treatment for this indication.
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